<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05084677</url>
  </required_header>
  <id_info>
    <org_study_id>202020080608084322319</org_study_id>
    <nct_id>NCT05084677</nct_id>
  </id_info>
  <brief_title>Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer</brief_title>
  <official_title>Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: An Open-Label, Single-Arm, Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the efficacy and tolerance of adding toripalimab simultaneously and subsequently&#xD;
      to concurrent platinum-based chemoradiotherapy in patients with locally advanced cervical&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to now, there have been several prospective studies exploring the effectiveness of PD-1&#xD;
      inhibitors in patients with recurrent/ metastatic cervical cancer. The results showed that&#xD;
      the overall objective response rate (ORR) was between 12.2% and 55.6%, and pembrolizumab was&#xD;
      approved by the US Food and Drug Administration for patients with advanced PD-L1-positive&#xD;
      cervical cancer who experienced progression during or after chemotherapy. However, the&#xD;
      evidence of using PD-1 inhibitors together with concurrent chemotheradiotherapy in patients&#xD;
      with locally advanced cervical cancer is rare, so we initiated this single arm prospective&#xD;
      phase II clinical study. The purpose is to explore the efficacy and tolerance of adding&#xD;
      toripalimab simultaneously and subsequently to concurrent chemoradiotherapy in patients with&#xD;
      locally advanced cervical cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of patients with at least one tumor scan of complete response (CR) or partial response (PR) using RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time from diagnosis of disease to disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time from diagnosis of disease of treatment until death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>PD-1 arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-1 concurrent with and subsequent after concurrent chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy</intervention_name>
    <description>Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) concurrent with chemoradiotherapy; 6 cycles of Toripalimab 240mg intravenously(IV) every 3 weeks (Q3W) after chemoradiotherapy; Toripalimab 240mg intravenously(IV) every 6 weeks (Q6W) thereafter until the whole treatment period reached one year since the beginning.</description>
    <arm_group_label>PD-1 arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 75;&#xD;
&#xD;
          -  Untreated patients with pathologically proven locally advanced cervical cancer;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1&#xD;
&#xD;
          -  Adequate hematological, renal and hepatic functions:&#xD;
&#xD;
               1. Hemoglobin &gt; 8.0 g/dl&#xD;
&#xD;
               2. Neutrophils &gt; 2000 cells/μl; Leukocytes &gt; 4 × 109/L&#xD;
&#xD;
               3. Platelets &gt; 100 × 109/L&#xD;
&#xD;
             g. Serum urea nitrogen (BUN) ≤ 1.5 × upper normal limit (UNL) h. Serum creatinine (Cr)&#xD;
             ≤ 1.5 × upper normal limit (UNL) d. Serum ALT/AST ≤ 2.5× UNL e. Serum Total bilirubin&#xD;
             ≤ 1.5× UNL&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  Eligible for concurrent chemoradiotherapy assessed by principle investigator;&#xD;
&#xD;
          -  No obvious active bleeding;&#xD;
&#xD;
          -  Written informed consent must be available before study registration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recurrent or distant metastatic disease;&#xD;
&#xD;
          -  Prior malignancies (other than curable non-melanoma skin cancer) within 5 years;&#xD;
&#xD;
          -  Active autoimmune diseases requiring systemic treatment or other diseases requiring&#xD;
             long-term use of substantial amount of hormones or other immunosuppressants;&#xD;
&#xD;
          -  Patients who need to receive systemic corticosteroids (dose equivalent to or higher&#xD;
             than prednisone 10mg qd) or other immunosuppressants within 14 days before enrollment&#xD;
             or during the study;&#xD;
&#xD;
          -  Vaccination of live attenuated vaccine 30 days before enrollment, or planned&#xD;
             vaccination of live attenuated vaccine during the study;&#xD;
&#xD;
          -  Previous organ transplantation or HIV patients;&#xD;
&#xD;
          -  Allergic to macromolecular proteins /monoclonal antibodies, or to any test drug&#xD;
             component;&#xD;
&#xD;
          -  Active acute or chronic viral hepatitis B or C. Hepatitis B virus (HBV) DNA&gt; 2000IU/ml&#xD;
             or 104 copies/ml; hepatitis C virus (HCV) RNA&gt; 103 copies/ml.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jie Chen</last_name>
    <phone>+86-18622221202</phone>
    <email>tjcjvip@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chen Li</last_name>
    <phone>+86-15510932601</phone>
    <email>771016127@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute&amp;Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Chen</last_name>
      <phone>+86-18622221202</phone>
      <email>tjcjvip@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Chen Li</last_name>
      <phone>+86-15510932601</phone>
      <email>771016127@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

